C4 THERAPEUTICS INCCCCC
ASignal's systematic analysis rates CCCC as Neutral.
Reflects the latest available analysis · analyzed Sep 13, 2026
The case on CCCC
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin of 86.34% indicating pricing power
- Low debt-to-equity ratio of 0.23x suggesting strong financial health
- High cash position with current ratio of 5.45x and quick ratio of 5.29x
- RSI near 34, approaching oversold territory suggesting potential reversal
- Negative MACD and declining price momentum indicating bearish trend
- Negative free cash flow of $-43.66M and operating cash flow of $-84.87M
- Negative profit and operating margins (net margin: -289.44%, operating margin: -397.88%)
- Negative return on equity (-48.14%) and return on assets (-19.25%)
- Revenue growth weak at 2.80% year-over-year
- EV/EBITDA of -2.36x indicating unprofitability
See the full verdict on CCCC
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CCCC
Most investors never get a second opinion, let alone several. ASignal runs CCCC past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.